NAPSR News:J & J Innovation Teams up with Dana-Farber Cancer Institute For Lung Cancer Collaboration

WASHINGTON - July 11, 2014 - PRLog -- Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc. announced a 3 year immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute. Research scientists at Janssen will work with the research team at Dana-Farber’s Belfer Institute for Applied Cancer Science to explore various clinical settings for immuno-oncology agents in Janssen’s lung cancer discovery pipeline.

“We are thrilled to be working with the scientists at the Belfer Institute,” said Peter Lebowitz, Janssen Global Therapeutic Area Head, Oncology. “Their excellence in lung cancer translational research, which incorporates both tumor genetics and immunotherapy, will be critical to the development of personalized treatment options for patients in need.”

With the use of the Belfer Institute’s proprietary immuno-oncology lung platform and lung cancer disease expertise, the teams will also identify balanced immune-oncology drug combos and biomarkers thus characterizing the mechanisms of resistance.

“There is a growing recognition of the potential importance of immuno-oncology agents directed at a variety of cancers,” said Robert G. Urban, PhD, Head of Johnson & Johnson Innovation, Boston. “Through our collaboration with the Dana-Farber Cancer Institute, we will be able to increase the probability of success and decrease development times for our important immuno-oncology pipeline in the critical area of lung cancer.”

Lung cancer is the leading cancer killer in both men and women in the United States. In 1987, it surpassed breast cancer to become the leading cause of cancer deaths in women.1 (http://www.lung.org/lung-disease/lung-cancer/resources/fa...)

Janssen Oncology will continue to explore advanced research options for lung cancer based on its high unmet need.

The collaboration on the continuous research and development of a beneficial therapeutic breakthrough for lung cancer will certainly add an impactful boost to the oncology market sector, if successful. This will without a doubt bolster the need for both certified and qualified individuals to promote J & J’s diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to sell their product both proficiently and efficiently.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!
The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information.